Abstract
The causative agent of severe acute respiratory syndrome (SARS) has been identified as a new type of coronavirus. Here, we have investigated the ability of adenoviral delivery of codon-optimised SARS-CoV strain Urbani structural antigens spike protein S1 fragment, membrane protein, and nucleocapsid protein to induce virus-specific broad immunity in rhesus macaques. We immunised rhesus macaques intramuscularly with a combination of the three Ad5-SARS-CoV vectors or a control vector and gave a booster vaccination on day 28. The vaccinated animals all had antibody responses against spike protein S1 fragment and T-cell responses against the nucleocapsid protein. All vaccinated animals showed strong neutralising antibody responses to SARS-CoV infection in vitro. These results show that an adenoviral-based vaccine can induce strong SARS-CoV-specific immune responses in the monkey, and hold promise for development of a protective vaccine against the SARS causal agent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1895-1896 |
| Number of pages | 2 |
| Journal | Lancet |
| Volume | 362 |
| Issue number | 9399 |
| DOIs | |
| State | Published - Dec 6 2003 |
| Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by National Heart Lung and Blood Institute, Program of Excellence in Gene Therapy supplement Grants U01 HL66949–01S1 to A Gambotto. The authors thank K Okada and H Sun for assistance with adenoviral preparation. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in the writing of the report.
